HMGCR positively regulated the growth and migration of glioblastoma cells

Gene

Volumn 576, Issue 1, 2016, Pages 22-27

  Qiu, Zhihua ^a   Yuan, Wen ^a   Chen, Tao ^b   Zhou, Chenzhi ^b   Liu, Chao ^a   Huang, Yongkai ^a   Han, Deqing ^a   Huang, Qinghui ^b,c  

^a ZHUZHOU CENTRAL HOSPITAL   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Cell growth and migration; Glioblastoma; Hippo pathway; HMGCR

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MEVALONIC ACID; TAZ PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; CTGF PROTEIN, HUMAN; HMGCR PROTEIN, HUMAN; TAZ PROTEIN, HUMAN; TUMOR PROTEIN;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; CELL MOTION; CELL PROLIFERATION; ENZYMOLOGY; GENETICS; HEK293 CELL LINE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CONNECTIVE TISSUE GROWTH FACTOR; GLIOBLASTOMA; HEK293 CELLS; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; NEOPLASM METASTASIS; NEOPLASM PROTEINS; TRANSCRIPTION FACTORS;

EID: 84946224746     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2015.09.067     Document Type: Article

References (29)

1. Awad A.J., Burns T.C., Zhang Y., Abounader R. Targeting MET for glioma therapy. Neurosurg. Focus. 2014, 37.
2. Breitling R., Krisans S.K. A second gene for peroxisomal HMG-CoA reductase? A genomic reassessment. J. Lipid Res. 2002, 43:2031-2036.
3. Butt S., Butt T., Jirstrom K., Hartman L., Amini R.M., Zhou W., Warnberg F., Borgquist S. The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy. Ann. Surg. Oncol. 2014, 21:2911-2919.
4. Clendening J.W., Pandyra A., Boutros P.C., El Ghamrasni S., Khosravi F., Trentin G.A., Martirosyan A., Hakem A., Hakem R., Jurisica I. Dysregulation of the mevalonate pathway promotes transformation. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:15051-15056.
5. DeSantis C.E., Lin C.C., Mariotto A.B., Siegel R.L., Stein K.D., Kramer J.L., Alteri R., Robbins A.S., Jemal A. Cancer treatment and survivorship statistics, 2014. CA Cancer J. Clin. 2014, 64:252-271.
6. Dricu A., Wang M., Hjertman M., Malec M., Blegen H., Wejde J., Carlberg M., Larsson O. Mevalonate-regulated mechanisms in cell growth control: role of dolichyl phosphate in expression of the insulin-like growth factor-1 receptor (IGF-1R) in comparison to Ras prenylation and expression of c-myc. Glycobiology 1997, 7:625-633.
7. Ernst A., Campos B., Meier J., Devens F., Liesenberg F., Wolter M., Reifenberger G., Herold-Mende C., Lichter P., Radlwimmer B. De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures. Oncogene 2010, 29:3411-3422.
8. Hamm R., Chen Y.R., Seo E.J., Zeino M., Wu C.F., Muller R., Yang N.S., Efferth T. Induction of cholesterol biosynthesis by archazolid B in T24 bladder cancer cells. Biochem. Pharmacol. 2014, 91:18-30.
9. Hamm R., Zeino M., Frewert S., Efferth T. Up-regulation of cholesterol associated genes as novel resistance mechanism in glioblastoma cells in response to archazolid B. Toxicol. Appl. Pharmacol. 2014, 281:78-86.
10. He Q., Huang H.Y., Zhang Y.Y., Li X., Qian S.W., Tang Q.Q. TAZ is downregulated by dexamethasone during the differentiation of 3T3-L1 preadipocytes. Biochem. Biophys. Res. Commun. 2012, 419:573-577.
11. Lavado A., He Y., Pare J., Neale G., Olson E.N., Giovannini M., Cao X. Tumor suppressor Nf2 limits expansion of the neural progenitor pool by inhibiting Yap/Taz transcriptional coactivators. Development (Cambridge, England) 2013, 140:3323-3334.
12. Lavado A., Ware M., Pare J., Cao X. The tumor suppressor Nf2 regulates corpus callosum development by inhibiting the transcriptional coactivator Yap. Development (Cambridge, England) 2014, 141:4182-4193.
13. Lignitto L., Arcella A., Sepe M., Rinaldi L., Delle Donne R., Gallo A., Stefan E., Bachmann V.A., Oliva M.A., Tiziana Storlazzi C. Proteolysis of MOB1 by the ubiquitin ligase praja2 attenuates Hippo signalling and supports glioblastoma growth. Nat. Commun. 2013, 4:1822.
14. Lin C., Yao E., Chuang P.T. A conserved MST1/2-YAP axis mediates Hippo signaling during lung growth. Dev. Biol. 2015.
15. Lipkin S.M., Chao E.C., Moreno V., Rozek L.S., Rennert H., Pinchev M., Dizon D., Rennert G., Kopelovich L., Gruber S.B. Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev. Res. (Phila.) 2010, 3:597-603.
16. Liu A.M., Xu M.Z., Chen J., Poon R.T., Luk J.M. Targeting YAP and Hippo signaling pathway in liver cancer. Expert Opin. Ther. Targets 2010, 14:855-868.
17. Lutz R.J., McLain T.M., Sinensky M. Feedback inhibition of polyisoprenyl pyrophosphate synthesis from mevalonate in vitro. Implications for protein prenylation. J. Biol. Chem. 1992, 267:7983-7986.
18. Pan D. The hippo signaling pathway in development and cancer. Dev. Cell 2010, 19:491-505.
19. Piccolo S., Dupont S., Cordenonsi M. The biology of YAP/TAZ: Hippo signaling and beyond. Physiol. Rev. 2014, 94:1287-1312.
20. Rilling H.C., Bruenger E., Leining L.M., Buss J.E., Epstein W.W. Differential prenylation of proteins as a function of mevalonate concentration in CHO cells. Arch. Biochem. Biophys. 1993, 301:210-215.
21. Rios-Marco P., Martin-Fernandez M., Soria-Bretones I., Rios A., Carrasco M.P., Marco C. Alkylphospholipids deregulate cholesterol metabolism and induce cell-cycle arrest and autophagy in U-87 MG glioblastoma cells. Biochim. Biophys. Acta 2013, 1831:1322-1334.
22. Romao L.F., Mendes F.A., Feitosa N.M., Faria J.C., Coelho-Aguiar J.M., de Souza J.M., Moura Neto V., Abreu J.G. Connective tissue growth factor (CTGF/CCN2) is negatively regulated during neuron-glioblastoma interaction. PLoS One 2013, 8.
23. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64:9-29.
24. Sorrentino G., Ruggeri N., Specchia V., Cordenonsi M., Mano M., Dupont S., Manfrin A., Ingallina E., Sommaggio R., Piazza S. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat. Cell Biol. 2014, 16:357-366.
25. Striedinger K., VandenBerg S.R., Baia G.S., McDermott M.W., Gutmann D.H., Lal A. The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. Neoplasia (New York, NY) 2008, 10:1204-1212.
26. Tang Y., Rowe R.G., Botvinick E.L., Kurup A., Putnam A.J., Seiki M., Weaver V.M., Keller E.T., Goldstein S., Dai J. MT1-MMP-dependent control of skeletal stem cell commitment via a beta1-integrin/YAP/TAZ signaling axis. Dev. Cell 2013, 25:402-416.
27. Wang X., Huang X., Yang Z., Gallego-Perez D., Ma J., Zhao X., Xie J., Nakano I., Lee L.J. Targeted delivery of tumor suppressor microRNA-1 by transferrin-conjugated lipopolyplex nanoparticles to patient-derived glioblastoma stem cells. Curr. Pharm. Biotechnol. 2014, 15:839-846.
28. Xu Y., Stamenkovic I., Yu Q. CD44 attenuates activation of the Hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res. 2010, 70:2455-2464.
29. Yang R., Wu Y., Wang M., Sun Z., Zou J., Zhang Y., Cui H. HDAC9 promotes glioblastoma growth via TAZ-mediated EGFR pathway activation. Oncotarget 2015, 6:7644-7656.